MOG and myeloid sarcoma: In these experiments, animals were treated with anti-DEC-205-myelin oligodendrocyte glycoprotein (MOG35-55) chimeric antibody (designated as anti-DEC-205-MOG or anti-DEC-MOG) to deliver the neural antigen MOG to cDC1 under non-inflammatory conditions, resulting in a prevention of specific autoimmune responses and disease symptoms of experimental autoimmune encephalomyelitis (EAE), a murine model of multiple sclerosis (MS) [36].